leisure time -WSS

leisure time

author：focus 2025-08-25 08:45:09 - browse：7394

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

WSS

Using force crossed my mind when examining a defiant young patient

Alabama IVF ruling threatens families facing fatal genetic disease

Medicare inequities exacerbate Puerto Rico’s health disparities

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Childhood vaccination ad campaign launches in the U.K.

focus

leisure time

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Medical leaders decry Supreme Court decision on affirmative action

The Harvard botanist who searched for psychedelics in the Amazon

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Dobbs anniversary: the lost opportunity of abortion as health care

PBM reform efforts get punted in Congress

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Community Health Systems hospitals under DOJ investigation

hotspot

Medicare Advantage isn’t working — for anyone

CDC panel: People 65 and older should get a Covid spring booster shot

Using force crossed my mind when examining a defiant young patient

Medicare Advantage isn’t working — for anyone

Elisabeth Bik tackles the widespread issue of research misconduct

Alabama hospital puts IVF treatments on hold

focus

entertainment

hotspot

entertainment